Premium
Perinatal outcomes following cell‐free DNA screening in >32 000 women: Clinical follow‐up data from a single tertiary center
Author(s) -
Liang Dong,
Lin Ying,
Qiao Fengchang,
Li Hang,
Wang Yan,
Zhang Jingjing,
Liu An,
Ji Xiuqing,
Ma Dingyuan,
Jiang Tao,
Hu Ping,
Xu Zhengfeng
Publication year - 2018
Publication title -
prenatal diagnosis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.956
H-Index - 97
eISSN - 1097-0223
pISSN - 0197-3851
DOI - 10.1002/pd.5328
Subject(s) - cell free fetal dna , medicine , trisomy , copy number variation , aneuploidy , cohort , obstetrics , pregnancy , human genetics , prenatal diagnosis , fetus , genome , biology , genetics , chromosome , gene
Objective Cell‐free DNA (cfDNA) screening for aneuploidy was clinically introduced in 2011. We aim to focus on the follow‐up information from a single tertiary center undergoing genome‐wide cfDNA screening to evaluate this technology. Method A total of 32 431 cases were retrospectively reviewed. The screening was performed using a BGI protocol, and the cfDNA results were analyzed together with the pregnancy outcomes, confirmatory testing results, and ultrasound findings. Results Of the 32 431 cfDNA screening cases, successful follow‐up was conducted in 287 (82.2%) cases with high‐risk cfDNA results, 85 (94.4%) cases with copy number variation (CNV) and rare autosomal trisomy (RAT) results, and 26 060 (81.5%) cases with low‐risk cfDNA results. Among them, 234 with high‐risk cfDNA results chose invasive testing, revealing 169 true positive cases. In cases with CNV and RAT results, 45 cases underwent invasive diagnosis, revealing six pathogenic CNVs and three uniparental disomies. In cases with low‐risk cfDNA results, three false negative cases were confirmed. Conclusion Cell‐free DNA screening appears to be effective in detecting the common autosomal aneuploidies, but one‐third of our cohort with high‐risk results rejected confirmatory testing. Our data provide information on the clinical experience of large‐scale whole‐genome cfDNA screening that has global relevance for the implementation of this technology.